I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

AMENDMENT UNDER 37 CFR 1.111 Examining Group 1609 Patent Application Docket No. GJE-7147

December 20, 2007:

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Sahar Javanmard

Art Unit

1609

Applicants

Robin Mark Bannister et al.

Serial No.

10/517,881

Filed:

December 13, 2004

Conf. No.

1605

For

Use of Nefopam for the Treatment of Nausea or Emesis

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA. 22313-1450

AMENDMENT UNDER 37 CFR §1.111

Sir:

An Extension of Time is being authorized with the electronic filing of this paper.

In response to the Office Action dated July 25, 2007, please amend the above-referenced application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims beginning on page 3 of this paper.

Remarks/Arguments follow the amendment section of this paper.